Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence
Detection of the Occurrence of Infiltration of Gadolinium Injection in Brain MR Scans Using Artificial Intelligence
1 other identifier
observational
40
1 country
1
Brief Summary
The purpose of this research is to develop machine learning algorithms to analyze images from brain MRI to confirm that contrast agent has been correctly administered.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 19, 2022
CompletedFirst Posted
Study publicly available on registry
February 11, 2022
CompletedStudy Start
First participant enrolled
March 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 5, 2022
CompletedApril 11, 2022
April 1, 2022
22 days
January 19, 2022
April 8, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Detection of Infiltration of Gadolinium contrast agent into tissue and muscle using artificial intelligence model
Correct detection of the presence of infiltration of Gadolinium contrast agent into tissue and muscleusing an artificial intelligence model. This outcome will be determined by measuring the difference in signal enhancement in the nasal mucosa or the lack of signal enhancement within the nasal mucosa.
2 months
Eligibility Criteria
Adults undergoing MR brain without and with IV contrast examination as part of their care plan.
You may qualify if:
- Patients undergoing a MR brain without and with contrast examination on any GE or Siemens 1.5T and 3T MRI system within Mayo Clinic, Rochester, as part of their care plan.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
James Pipe, PhD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 19, 2022
First Posted
February 11, 2022
Study Start
March 14, 2022
Primary Completion
April 5, 2022
Study Completion
April 5, 2022
Last Updated
April 11, 2022
Record last verified: 2022-04